Every Form 4 that Fate Therapeutics, Inc. (FATE) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow FATE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FATE filings page.
Fate Therapeutics’ Chief Legal and Compliance Officer, Cindy Tahl, reported a sale of 38,800 shares of common stock on August 4, 2026 at a weighted average price of $2.4589 per share, with prices ranging from $2.415 to $2.540.
The shares were sold to cover tax withholding obligations in connection with the vesting of 75,000 shares of common stock underlying RSUs granted on July 29, 2024, through automatic “sell-to-cover” transactions executed under an irrevocable election and not at her discretion. After these transactions, she directly holds 589,355 shares of Fate Therapeutics common stock.
Fate Therapeutics reported that President and CEO Bahram Valamehr sold 43,947 shares of common stock on August 4, 2026 at a weighted average price of $2.4598 per share, with individual trades between $2.415 and $2.540. The sale covered tax withholding arising from vesting of 75,000 RSU-based shares and was automatically executed under an irrevocable sell-to-cover election, not at his discretion. After this transaction, he directly holds 591,815 shares of Fate Therapeutics common stock.
Fate Therapeutics reported that an entity associated with Redmile Group received a new stock option award linked to board service. The option covers 87,900 shares of common stock at an exercise price of $2.06 per share and expires on June 12, 2036. It was granted to director Michael Lee for his role on the board, but, under Redmile’s policies, he holds it as a nominee for the sole benefit of Redmile, which has the economic and voting rights. The option will vest in full on the earlier of June 12, 2027 or the date of the company’s 2027 annual stockholder meeting, subject to Lee’s continued board service. Redmile and principal Jeremy Green disclaim beneficial ownership except to any pecuniary interest they may have.
Fate Therapeutics director Michael Stewart Lee received a grant of stock options as compensation for his board service. The award covers 87,900 stock options to purchase common shares at an exercise price of $2.06 per share, expiring on June 12, 2036. The options vest in full on the earlier of June 12, 2027 or the company’s 2027 annual stockholders’ meeting, subject to his continued board service. The grant is held by Lee as a nominee for Redmile Group, LLC, which holds the economic and voting rights, and both Lee and Redmile parties disclaim beneficial ownership except to the extent of any pecuniary interest.
Fate Therapeutics director Yuan Xu received a new stock option grant as board compensation. The award covers 87,900 shares of common stock at an exercise price of $2.06 per share and is held directly. Following this grant, Xu holds options on 87,900 underlying shares.
The option vests and becomes exercisable on the earlier of June 12, 2027 or the date of Fate Therapeutics’ 2027 annual stockholder meeting, as long as Xu continues serving on the board. This is a non-employee director equity grant under the company’s compensation policy, not an open-market purchase or sale.
FATE Therapeutics director Karin Jooss received a routine stock option grant as part of non-employee director compensation. She was awarded options for 87,900 shares of common stock at an exercise price of $2.06 per share, expiring in 2036. The options vest on the earlier of June 12, 2027 or the company’s 2027 annual stockholder meeting, subject to continued board service, and represent compensation rather than an open-market purchase or sale.
Fate Therapeutics director Robert S. Epstein received a grant of stock options covering 87,900 shares of common stock. The options have an exercise price of $2.06 per share and expire on June 12, 2036. This award was issued under the company’s Amended and Restated Non-Employee Director Compensation Policy as an annual equity grant for non-employee directors.
The options will vest and become exercisable on the earlier of June 12, 2027 or the date of Fate Therapeutics’ 2027 Annual Meeting of Stockholders, as long as Epstein continues to serve on the board. After this grant, he holds 87,900 options directly.
Fate Therapeutics director Shefali Agarwal received a new stock option grant covering 87,900 shares of common stock. The option has an exercise price of $2.06 per share and expires on June 12, 2036. It will vest and become exercisable on the earlier of June 12, 2027 or the company’s 2027 Annual Meeting of Stockholders, contingent on her continued board service. Following this grant, she holds options on 87,900 shares directly.
FATE Therapeutics director Matt Abernethy received a new stock option grant covering 87,900 shares of common stock. The option has an exercise price of $2.06 per share and expires on June 12, 2036.
The grant was made under the company’s Amended and Restated Non-Employee Director Compensation Policy, which provides annual equity awards on the date of the Annual Meeting of Stockholders. These options vest and become exercisable on the earlier of June 12, 2027 or the date of the 2027 Annual Meeting, as long as Abernethy continues to serve on the board.
Fate Therapeutics director William H. Rastetter received a grant of stock options covering 87,900 shares of Common Stock. The options have an exercise price of $2.06 per share and expire on June 12, 2036.
The grant was made under the company’s Amended and Restated Non-Employee Director Compensation Policy, which provides annual equity awards to non-employee directors on the date of the Annual Meeting of Stockholders. These options vest and become exercisable on the earlier of June 12, 2027 or the date of the 2027 Annual Meeting of Stockholders, subject to his continued service on the Board. Following this grant, he holds 87,900 options according to this filing.
Fate Therapeutics director Laura Hamill received a grant of stock options to acquire 175,800 shares of Common Stock. The options have an exercise price of $2.06 per share and expire on June 12, 2036. This grant was made under the company’s Amended and Restated Non-Employee Director Compensation Policy, which provides equity upon a director’s appointment or election. The options vest in 36 equal monthly installments starting on June 12, 2026 and will be fully vested on June 12, 2029, contingent on Hamill’s continued service on the Board.
Fate Therapeutics officer Cindy Tahl reported an open-market sale of 25,590 shares of common stock at a weighted average price of $1.879 per share. The company states the shares were sold solely to cover tax withholding on the vesting of 50,000 performance-based RSUs granted on July 29, 2024, under a pre-arranged sell-to-cover election rather than at her discretion.
After these tax-related sales, Tahl directly holds 628,155 shares of Fate Therapeutics common stock.
Fate Therapeutics President and CEO Bahram Valamehr reported an automatic sale of 28,946 shares of Common Stock. The shares were sold on open market on May 20, 2026 at a weighted average price of $1.8822 per share to cover tax withholding obligations tied to the vesting of 50,000 performance-based RSUs granted on July 29, 2024. The transactions were executed pursuant to a prior irrevocable sell-to-cover election and were not made at his discretion. Following these sales, Valamehr continues to hold 635,762 shares directly.
Fate Therapeutics officer Cindy Tahl exercised stock options to acquire a total of 166,664 shares of common stock on May 6, 2026. She exercised 44,444 options at $1.05 per share and 122,220 options at $1.32 per share, with no open-market sales reported. Following these transactions, she directly holds 653,745 shares of common stock. The options exercised relate to grants that vest in 36 equal monthly installments starting January 1, 2025 and January 1, 2026, becoming fully vested in 2028 and 2029, subject to her continued service.
Fate Therapeutics director Robert S. Epstein exercised stock options to acquire 25,000 shares of Common Stock at $1.69 per share. The options related to shares that vested on the date of the company’s 2017 Annual Meeting of Stockholders. After the transaction, he directly holds 36,331 Fate Therapeutics shares.
FATE Therapeutics director William H. Rastetter exercised stock options to acquire 25,000 shares of Common Stock at $1.69 per share. Following the exercise, he holds 36,331 Common shares directly. In addition, 459,272 shares are held indirectly by The Investment 2002 Trust and 146,821 shares are held indirectly by The Rastetter Family Trust, where he serves in trustee roles.
Fate Therapeutics shareholder Redmile Group filed an amended Form 4 to update the terms of cash-settled swap positions tied to Fate common stock. The amendment corrects the reference price associated with swap agreements that were internally reorganized.
The swaps, representing an economic interest in 266,280 notional shares of common stock per reported leg, were novated from RedCo II Master Fund to two wholly owned subsidiaries on a pro‑rata basis, for no consideration and with no change in other terms. Footnotes state this internal reorganization caused no change in the aggregate beneficial ownership or economic exposure of Redmile or its principal Jeremy Green.
The swaps are cash‑settled and give Redmile-managed clients economic exposure to Fate’s share price movements without voting, investment, or dispositive control over Fate shares. Cash flows at settlement depend on the difference between the corrected reference price of $5.84 per notional share and the market price at close‑out.
Fate Therapeutics insider RedCo II Master Fund, L.P., an investment vehicle managed by Redmile Group, completed an internal reorganization of its holdings. RedCo II distributed its Fate Therapeutics common stock, Class A convertible preferred stock, pre-funded warrants, and cash-settled swaps pro rata and in kind to two wholly owned subsidiaries, for no consideration.
Following this, RedCo II no longer has voting or dispositive power over these securities, is no longer a more-than-10% beneficial owner, and will be dissolved. The filing states the reorganization caused no change in the aggregate beneficial ownership of Redmile Group or its principal, Jeremy Green.
Fate Therapeutics reported new equity awards to Chief Legal and Compliance Officer Cindy Tahl. On January 15, 2026, she was granted 100,000 shares of common stock at an acquisition price of $0.00, reported as an award of restricted stock units. These RSUs vest in four equal installments on January 8, 2027, 2028, 2029 and 2030, with each RSU converting into one share of common stock upon settlement. Following this grant, she beneficially owns 487,081 common shares directly.
She was also granted a stock option for 400,000 shares of common stock with an exercise price of $1.05 per share. This option vests in 36 equal monthly installments after January 1, 2026, becoming fully vested and exercisable on January 1, 2029, contingent on continued service with the company.
Fate Therapeutics Chief Financial Officer Adawi Kamal reported new equity awards, including restricted stock units and stock options. On January 15, 2026, Kamal received 25,000 restricted stock units that vest in four equal installments on January 8 of each year from 2027 through 2030, subject to continued service. Each unit represents the right to receive one share of common stock upon settlement.
Kamal was also granted stock options for 75,000 shares of common stock at an exercise price of $1.05 per share. These options vest in 36 equal monthly installments following January 1, 2026, becoming fully vested and exercisable on January 1, 2029, if service continues. After these grants, Kamal beneficially owned 100,000 shares of common stock directly and held 75,000 stock options.
Fate Therapeutics reported that its President and CEO, Bahram Valamehr, received new equity awards. On January 15, 2026, he was granted 335,000 shares of common stock at a price of $0.00, representing restricted stock units that vest in four equal parts on January 8 of 2027, 2028, 2029 and 2030, contingent on continued service. On the same date, he was also granted a stock option for 1,300,000 shares of common stock at an exercise price of $1.05 per share, vesting in 36 equal monthly installments after January 1, 2026, and becoming fully vested on January 1, 2029, subject to continued service. Following the stock award, he beneficially owned 664,708 shares of common stock directly, and held 1,300,000 stock options directly.
Fate Therapeutics Chief Legal and Compliance Officer Cindy Tahl reported an automatic sale of company stock tied to restricted stock unit (RSU) vesting. On January 9, 2026, she sold 10,589 shares of common stock at a weighted average price of $1.0648 per share, with individual sale prices ranging from $1.05 to $1.09. The filing explains these were the required number of shares sold to cover tax withholding obligations arising from the vesting of 17,500 RSU-based shares granted on January 15, 2025 and 8,326 RSU-based shares granted on January 25, 2022. The transactions were executed under a pre-arranged “sell-to-cover” election and were not made at her discretion. After the sales, Tahl beneficially owned 387,081 shares of Fate Therapeutics common stock directly.
Fate Therapeutics President and CEO Bahram Valamehr reported the sale of 5,190 shares of the company’s common stock on January 9, 2026 at a weighted average price of $1.0708 per share. After this transaction, he beneficially owned 329,708 shares.
According to the filing, the shares were sold only in an amount required to cover tax withholding obligations arising from the vesting of 8,326 shares underlying previously granted RSUs. The sales were automatically executed under an irrevocable sell-to-cover election and were not made at his discretion.